相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Targeted suppression of human IBD-associated gut microbiota commensals by phage consortia for treatment of intestinal inflammation
Sara Federici et al.
CELL (2022)
Functional Restoration of Bacteriomes and Viromes by Fecal Microbiota Transplantation
Kosuke Fujimoto et al.
GASTROENTEROLOGY (2021)
Complete genome sequence of the newly discovered temperate Clostridioides difficile bacteriophage phiCDKH01 of the family Siphoviridae
Krzysztof Hinc et al.
ARCHIVES OF VIROLOGY (2021)
Characterization of an Endolysin Targeting Clostridioides difficile That Affects Spore Outgrowth
Shakhinur Islam Mondal et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Isolation and Characterization of the Novel Phage JD032 and Global Transcriptomic Response during JD032 Infection of Clostridioides difficile Ribotype 078
Tinghua Li et al.
MSYSTEMS (2020)
Metagenome Data on Intestinal Phage-Bacteria Associations Aids the Development of Phage Therapy against Pathobionts
Kosuke Fujimoto et al.
CELL HOST & MICROBE (2020)
Phage Therapy: A Renewed Approach to Combat Antibiotic-Resistant Bacteria
Kaitlyn E. Kortright et al.
CELL HOST & MICROBE (2019)
Clostridium difficile infection: review
Jacek Czepiel et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2019)
Antibiotics: past, present and future
Matthew I. Hutchings et al.
CURRENT OPINION IN MICROBIOLOGY (2019)
Drug-Resistant E. coli Bacteremia Transmitted by Fecal Microbiota Transplant
Zachariah DeFilipp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
A Novel Bacteriophage Lysin-Human Defensin Fusion Protein Is Effective in Treatment of Clostridioides difficile Infection in Mice
Zhong Peng et al.
FRONTIERS IN MICROBIOLOGY (2019)
Faecal Microbiota Transplantation Eradicated Extended-Spectrum Beta-Lactamase-Producing Klebsiella pneumoniae from a Renal Transplant Recipient with Recurrent Urinary Tract Infections
Anne Karmisholt Grosen et al.
CASE REPORTS IN NEPHROLOGY AND DIALYSIS (2019)
Phage Endolysins as Potential Antimicrobials against Multidrug Resistant Vibrio alginolyticus and Vibrio parahaemolyticus: Current Status of Research and Challenges Ahead
Nandita Matamp et al.
MICROORGANISMS (2019)
Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)
L. Clifford McDonald et al.
CLINICAL INFECTIOUS DISEASES (2018)
Extremely and pandrug-resistant bacteria extra-deaths: myth or reality?
Cedric Abat et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2018)
Phage-Derived Peptidoglycan Degrading Enzymes: Challenges and Future Prospects for In Vivo Therapy
Hugo Oliveira et al.
VIRUSES-BASEL (2018)
Development of Phage Lysins as Novel Therapeutics: A Historical Perspective
Vincent A. Fischetti
VIRUSES-BASEL (2018)
Bacteriophages are more virulent to bacteria with human cells than they are in bacterial culture; insights from HT-29 cells
Jinyu Shan et al.
SCIENTIFIC REPORTS (2018)
The Novel Phages phiCD5763 and phiCD2955 Represent Two Groups of Big Plasmidial Siphoviridae Phages of Clostridium difficile
Gabriel Ramirez-Vargas et al.
FRONTIERS IN MICROBIOLOGY (2018)
Characterization of Bacteriophages Infecting Clinical Isolates of Clostridium difficile
Wichuda Phothichaisri et al.
FRONTIERS IN MICROBIOLOGY (2018)
A Clostridioides difficile bacteriophage genome encodes functional binary toxin-associated genes
Thomas Riedel et al.
JOURNAL OF BIOTECHNOLOGY (2017)
Editorial: Phage Therapy: Past, Presentand Future
Stephen T. Abedon et al.
FRONTIERS IN MICROBIOLOGY (2017)
Pharmacokinetics and Tolerance of the Phage Endolysin-Based Candidate Drug SAL200 after a Single Intravenous Administration among Healthy Volunteers
Soo Youn Jun et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Bacteriophage Combinations Significantly Reduce Clostridium difficile Growth In Vitro and Proliferation In Vivo
Janet Y. Nale et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Newly identified bacteriolytic enzymes that target a wide range of clinical isolates of Clostridium difficile
Krunal K. Mehta et al.
BIOTECHNOLOGY AND BIOENGINEERING (2016)
Two Novel Myoviruses from the North of Iraq Reveal Insights into Clostridium difficile Phage Diversity and Biology
Srwa J. Rashid et al.
VIRUSES-BASEL (2016)
Will 10 Million People Die a Year due to Antimicrobial Resistance by 2050?
Marlieke E. A. de Kraker et al.
PLOS MEDICINE (2016)
'Get in Early'; Biofilm and Wax Moth (Galleria mellonella) Models Reveal New Insights into the Therapeutic Potential of Clostridium difficile Bacteriophages
Janet Y. Nale et al.
FRONTIERS IN MICROBIOLOGY (2016)
Using a Novel Lysin To Help Control Clostridium difficile Infections
Qiong Wang et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Characterization of Temperate Phages Infecting Clostridium difficile Isolates of Human and Animal Origins
Ognjen Sekulovic et al.
APPLIED AND ENVIRONMENTAL MICROBIOLOGY (2014)
European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection
S. B. Debast et al.
CLINICAL MICROBIOLOGY AND INFECTION (2014)
Toxin-Producing Clostridium difficile Strains as Long-Term Gut Colonizers in Healthy Infants
Ingegerd Adlerberth et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2014)
Molecular basis for bacterial peptidoglycan recognition by LysM domains
Stephane Mesnage et al.
NATURE COMMUNICATIONS (2014)
Evaluation of bacteriophage therapy to control Clostridium difficile and toxin production in an in vitro human colon model system
Emma Meader et al.
ANAEROBE (2013)
Fecal Transplant via Retention Enema for Refractory or Recurrent Clostridium difficile Infection
Zain Kassam et al.
ARCHIVES OF INTERNAL MEDICINE (2012)
Bacteriophage endolysins as novel antimicrobials
Mathias Schmelcher et al.
FUTURE MICROBIOLOGY (2012)
Regulated Virulence Controls the Ability of a Pathogen to Compete with the Gut Microbiota
Nobuhiko Kamada et al.
SCIENCE (2012)
Clostridium difficile infection Toxins and non-toxin virulence factors, and their contributions to disease establishment and host response
Gayatri Vedantam et al.
GUT MICROBES (2012)
Prophage-Stimulated Toxin Production in Clostridium difficile NAP1/027 Lysogens
Ognjen Sekulovic et al.
JOURNAL OF BACTERIOLOGY (2011)
Structure-Based Modification of a Clostridium difficile-Targeting Endolysin Affects Activity and Host Range
Melinda J. Mayer et al.
JOURNAL OF BACTERIOLOGY (2011)
Bacteriophage treatment significantly reduces viable Clostridium difficile and prevents toxin production in an in vitro model system
Emma Meader et al.
ANAEROBE (2010)
Genome analysis of the Clostridium difficile phage ΦCD6356, a temperate phage of the Siphoviridae family
Marianne Horgan et al.
GENE (2010)
Clostridium difficile 30 years on: what has, or has not, changed and why?
Dale N. Gerding
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2009)
Molecular characterization of a Clostridium difficile bacteriophage and its cloned biologically active endolysin
Melinda J. Mayer et al.
JOURNAL OF BACTERIOLOGY (2008)
LysM domains from Pteris ryukyuensis Chitinase-A -: A stability study and characterization of the chitin-binding site
Takayuki Ohnuma et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Morphological and genetic diversity of temperate phages in Clostridium difficile
Louis-Charles Fortier et al.
APPLIED AND ENVIRONMENTAL MICROBIOLOGY (2007)
The complete genome sequence of Clostridium difficile phage φC2 and comparisons to φCD119 and inducible prophages of CD630
Shan Goh et al.
MICROBIOLOGY-SGM (2007)
分享论文
